Barclays PLC Crinetics Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 207,712 shares of CRNX stock, worth $7.94 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

207,712

Previous 207,712 -0.0%

Holding current value

$7.94 Million

Previous $10.6 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$43.83 - $54.98 $3.92 Million - $4.91 Million	89,358 Added 75.5%	207,712 $10.6 Million
Q2 2024 Aug 14, 2024	BUY	$42.12 - $51.91 $1.83 Million - $2.26 Million	43,459 Added 58.03%	118,354 $5.3 Million
Q1 2024 May 15, 2024	SELL	$34.76 - $46.81 $4.04 Million - $5.43 Million	-116,089 Reduced 60.78%	74,895 $3.51 Million
Q4 2023 Feb 15, 2024	BUY	$25.62 - $37.07 $1.99 Million - $2.88 Million	77,702 Added 68.59%	190,984 $6.8 Million
Q3 2023 Nov 07, 2023	BUY	$15.97 - $30.59 $338,388 - $648,171	21,189 Added 23.01%	113,282 $3.37 Million
Q2 2023 Aug 03, 2023	SELL	$15.73 - $23.6 $270,241 - $405,448	-17,180 Reduced 15.72%	92,093 $1.66 Million
Q1 2023 May 04, 2023	BUY	$15.31 - $21.1 $618,983 - $853,073	40,430 Added 58.73%	109,273 $1.76 Million
Q4 2022 Feb 13, 2023	BUY	$15.49 - $19.05 $282,506 - $347,433	18,238 Added 36.04%	68,843 $1.26 Million
Q3 2022 Nov 03, 2022	BUY	$18.11 - $22.37 $843,255 - $1.04 Million	46,563 Added 1151.98%	50,605 $994,000
Q2 2022 Aug 12, 2022	SELL	$16.49 - $27.64 $89,771 - $150,472	-5,444 Reduced 57.39%	4,042 $75,000
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $828,362 - $1.37 Million	-48,301 Reduced 83.58%	9,486 $208,000
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $786,616 - $1.15 Million	40,652 Added 237.25%	57,787 $1.64 Million
Q3 2021 Nov 09, 2021	BUY	$16.88 - $25.23 $35,009 - $52,327	2,074 Added 13.77%	17,135 $361,000
Q2 2021 Aug 13, 2021	SELL	$15.9 - $21.15 $151,383 - $201,369	-9,521 Reduced 38.73%	15,061 $283,000
Q1 2021 May 13, 2021	BUY	$13.3 - $17.55 $181,864 - $239,978	13,674 Added 125.36%	24,582 $375,000
Q4 2020 Feb 11, 2021	SELL	$12.08 - $17.46 $40,262 - $58,194	-3,333 Reduced 23.4%	10,908 $153,000
Q3 2020 Nov 12, 2020	SELL	$13.62 - $17.66 $34,690 - $44,980	-2,547 Reduced 15.17%	14,241 $223,000
Q2 2020 Aug 12, 2020	BUY	$13.04 - $23.23 $171,189 - $304,963	13,128 Added 358.69%	16,788 $295,000
Q1 2020 May 13, 2020	SELL	$11.52 - $26.46 $86,837 - $199,455	-7,538 Reduced 67.32%	3,660 $54,000
Q4 2019 Feb 10, 2020	BUY	$15.24 - $25.09 $79,476 - $130,844	5,215 Added 87.16%	11,198 $281,000
Q3 2019 Nov 14, 2019	SELL	$14.91 - $25.01 $39,511 - $66,276	-2,650 Reduced 30.7%	5,983 $90,000
Q2 2019 Aug 14, 2019	BUY	$21.48 - $27.71 $71,120 - $91,747	3,311 Added 62.21%	8,633 $216,000
Q1 2019 May 15, 2019	BUY	$21.07 - $29.31 $112,134 - $155,987	5,322 New	5,322 $121,000
Q4 2018 Feb 14, 2019	SELL	$22.4 - $35.39 $58,419 - $92,297	-2,608 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$22.66 - $36.8 $59,097 - $95,974	2,608 New	2,608 $75,000

Others Institutions Holding CRNX

# of Institutions

243

Shares Held

80M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.05B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account